Loading
Neuro-oncologist whose neoadjuvant PD-1 trial showed immunotherapy before surgery can activate immune responses in glioblastoma.
Timothy Cloughesy led the randomised pilot trial showing neoadjuvant pembrolizumab before surgery for recurrent glioblastoma enhances intratumoural T-cell responses and was associated with longer survival than adjuvant-only dosing, a template for window-of-opportunity trials in brain tumours. He co-led the vocimagene (Toca 511) and GBM AGILE platform trial efforts and directs neuro-oncology at UCLA.
| Title | Journal | Year |
|---|---|---|
| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma | Nature Medicine | 2019 |
| Glioblastoma: from molecular pathology to targeted treatment | Annual Review of Pathology | 2014 |
Shares PD-1, Immune checkpoint inhibitors and the tags immunotherapy, neoadjuvant.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag neoadjuvant.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.